Patient adherence: The influence of non-virological factors in a real world setting
T Witthöft, R Link, S Christensen, HW Busch, W Gickler, H Steffens, C John, S Holm, A von Lucadou, E Zehnter, HJ Cordes, D Hüppe, H Blaak, A Heuser, M Bilzer · Zeitschrift für Gastroenterologie · 2012 · Heft 08
Bibliografische Angaben
Zusammenfassung
Aims: Only few data are available on adherence to combination HCV therapy with pegylated interferon (PegIFN)/ribavirin (RBV) in real-world settings, despite its acknowledged importance. Such information might help clinicians to improve adherence and thereby virologic response to PegIFN/RBV therapy, also in combination with new antivirals. Methods: In this prospective observational multicenter study (@dhere study) 746 treatment-naïve patients with chronic HCV infection were treated with PegIFN alfa-2b 1.5µg/kg/wk + weight-based RBV (800–1200mg/day) for up to 48 wks at 42 sites in Germany. Patients who received at…
